Bottom line
Is RYBOX a good fund? The bottom line
RYBOX is the Class A share class of Biotechnology Fund, an actively managed technology sector mutual fund from Guggenheim.
Annual fees run 1.63% — about $163 a year on every $10,000 invested, more expensive than 88% of technology sector funds we track.
It returned +24.2% over one year, +2.8% a year over five years, +5.1% a year over ten (as of Dec 31, 2025, per its prospectus).
With $137 million in net assets and 74 holdings, its largest position is Abbvie Inc (8.2%) and the top 10 make up 36.2% of the portfolio.
This share class carries a front-end sales charge of up to 4.75%; a no-load class or ETF alternative can avoid it.
The closest lower-cost alternative we found is IBBQ (0.19%, 58% top-holdings overlap).
What to watch
- Expensive for its category (1.63%)
- 5-year return in the bottom quarter of its category
- Front-end sales load up to 4.75%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What RYBOX invests in
The Biotechnology Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the biotechnology industry, including companies involved in research and development, genetic or other biological engineering, and in the design, manufacture, or sale of related biotechnology products or services (Biotechnology Companies).
Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Biotechnology Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor. The Fund may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations.…
From the fund's prospectus (filed Jul 29, 2026).
RYBOX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RYBOX | +24.2% | +2.8% | +5.1% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2025
What RYBOX costs
On a $10,000 investment, RYBOX's 1.63% expense ratio costs about $163 a year. The prospectus estimates $2,364 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
RYBOX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Abbvie Inc ABBV | 8.17% |
| 2 | Amgen Inc AMGN | 5.05% |
| 3 | Gilead Sciences Inc GILD | 4.49% |
| 4 | Vertex Pharmaceuticals Inc VRTX | 4.32% |
| 5 | Regeneron Pharmaceuticals Inc REGN | 2.93% |
| 6 | Revolution Medicines Inc RVMD | 2.48% |
| 7 | Alnylam Pharmaceuticals Inc ALNY | 2.36% |
| 8 | Beone Medicines Ltd ONC | 2.17% |
| 9 | Moderna Inc MRNA | 2.15% |
| 10 | Biogen Inc BIIB | 2.13% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 36.2% of the fund. See all top 25 holdings and asset mix →